Altamir - Registration Document 2016

1

FINANCIAL AND LEGAL INFORMATION Presentation and history of the Company

1.2.3 ALTAMIR PORTFOLIO

At 31 December 2016

Percentage interest in the underlying

Year of investment

operating company

Residual cost in €k

Stage of development

TMT (Technology – Media – Telecom) Marlink (1a) (2)

2016 2008 2016 2016 2007 2016 2011 2015 2016 2016 2015 2013 2015

27.30% 7.06% 21.09% 28.89% 35.30% 17.10% 0.96% 0.51% 0.57% 0.72% 0.97% 0.22% 7.53%

59,063

LBO

Altran Technologies* (3)

42,966 Growth capital

InfoVista (1a) (2)

39,071 33,911 24,568 20,575 11,505

LBO LBO LBO LBO LBO LBO LBO LBO LBO LBO

Melita (1a)

Gfi Informatique* (3)

Nowo/Oni (1a) Vocalcom (1a)

Growth capital

Exact Software (1b)

3,183 2,554 2,335 1,664 1,357

Engineering Ingegneria Informatica (1b)

Duck Creek Technologies (1b)

EVRY (1b)

GlobalLogic (1b)

Zensar* (1b)

1,126

243,878

HEALTHCARE Unilabs (3) (4)

2007 2011 2013 2016 2016 2014 2015

5.48% 13.42% 0.33% 0.91% 0.48% 0.33% 0.63%

22,548 14,041

LBO LBO LBO LBO LBO LBO LBO

Amplitude Surgical* (1a)

One Call Care Management (1b)

3,619 2,875 2,085

Invent Neurax (1b) Vyaire Medical (1b)

Genex (1b)

321 151

Ideal Protein (1b)

45,639

(1) Investments via the Apax funds (1a) via the Apax France VIII and Apax France IX funds (1b) via the Apax VIII LP and Apax IX LP funds (2) Co-investments (alongside the Apax France VIII and Apax France IX funds) (3) Direct investments (legacy portfolio) (4) Divestiture of Altamir’s direct investment and new investment in Unilabs via the Apax IX LP fund finalised in February 2017

*

Listed company.

20 REGISTRATION DOCUMENT 1 ALTAMIR 2016

WWW.ALTAMIR.FR